Adding sodium bicarbonate to lidocaine to enhance its efficacy during peripheral nerve block is controversial. The authors studied the effect of adding sodium bicarbonate to lidocaine with and without epinephrine versus equivalent alkalinization by sodium hydroxide (NaOH) on onset, degree, and duration of peripheral nerve block.
Part I examined alkalinization by sodium bicarbonate versus NaOH to pH 7.8 on 0.5% lidocaine, with and without epinephrine (1:100,000), prepared from crystalline salt. Part II examined 0.5% and 1.0% commercial lidocaine solutions, with and without epinephrine, either unalkalinized or alkalinized with sodium bicarbonate or NaOH. With NaOH, pH was adjusted to 7.8, but with sodium bicarbonate, no pH adjustments were made to simulate clinical conditions.
In part I, addition of either NaOH or sodium bicarbonate to 0.5% lidocaine without epinephrine produced a faster onset than did unalkalinized lidocaine, without effecting degree or duration of block. In solutions with epinephrine there were no differences in onset, degree, or duration between lidocaine alkalinized with sodium bicarbonate versus NaOH. In part II, addition of sodium bicarbonate or NaOH to 1.0% commercial lidocaine without epinephrine did not accelerate onset compared with the unalkalinized solution. However, adding sodium bicarbonate decreased the degree and duration of block by 25% and more than 50%, respectively, compared with lidocaine unalkalinized and alkalinized with NaOH. With epinephrine, sodium bicarbonate hastened onset without effecting degree and duration compared with the unalkalinized solution.
With 1% commercial lidocaine without epinephrine, sodium bicarbonate decreases the degree and duration of block. However, in solutions with epinephrine, sodium bicarbonate hastens onset, without effecting degree or duration.
MANY anesthesiologists believe that adding sodium bicarbonate to plain lidocaine hydrochloride can enhance the efficacy of this local anesthetic. This topic has been most widely investigated in epidural anesthesia. Studies have shown that adding sodium bicarbonate to lidocaine hydrochloride without epinephrine improves the quality of epidural block, whereas adding sodium bicarbonate to lidocaine with epinephrine does not. The addition of 8.4% sodium bicarbonate to 2% lidocaine hydrochloride without epinephrine (1:10, vol:vol) was shown to decrease onset time 1,2and enhance the depth of epidural block at L4–S1. 2When bicarbonate was added to 2% lidocaine hydrochloride with epinephrine (1:200,000), neither onset time nor depth of epidural block at L4–S1 roots was altered. 3
Most clinical investigators addressing this question have used epidural anesthesia as their paradigm. Accordingly, the clinical literature remains unclear as to whether adding sodium bicarbonate to either plain lidocaine or lidocaine with epinephrine improves the quality of peripheral nerve block. In addition, the effect of bicarbonate on lidocaine’s onset of action in peripheral nerve block remains controversial. For example, Chow et al. 4found that adding 8.4% sodium bicarbonate to 1.5% lidocaine hydrochloride (1:10) with epinephrine (1:200,000) did not speed the onset of analgesia in axillary brachial plexus block. However, adding sodium bicarbonate at the same concentration and volume ratio to 2% lidocaine, with and without epinephrine (1:100,000), did decrease the onset time of peribulbar anesthesia. 5Apart from effects on onset, the actions of bicarbonate on the depth and duration of peripheral nerve block with lidocaine has not been previously described.
In the present study we used a well-defined laboratory model, i.e. , sciatic nerve block in the rat, 6,7to address the effect of sodium bicarbonate on peripheral nerve block performed with lidocaine. We compared onset time, degree of impairment of nociception, i.e. , depth of analgesia, and block duration with different lidocaine solutions in rats receiving percutaneous sciatic nerve blocks. Lidocaine solutions, with and without epinephrine, were prepared from either crystalline salt or from a commercially available source (Abbott Laboratories, North Chicago, IL). These solutions were either not alkalinized (plain lidocaine), alkalinized with sodium bicarbonate, or alkalinized with sodium hydroxide (NaOH).
Materials and Methods
Male Sprague-Dawley rats (Taconic Farms, Germantown, NY) weighing 250–350 g were housed in the Brigham and Women’s Hospital animal facilities with a 12-h light–dark cycle. All behavioral testing and surgical procedures in this study were approved by the Harvard Medical Area Committee on Animals. All animals used in these experiments were handled for 15 min/day for a 2-week period before the tests to preclude stress-induced analgesia in rats during experimentation. Handling procedures involved persistent tactile contact with one experimenter (C.J.S.) and several applications of a deep pinch with serrated forceps to the fifth metatarsal. 6
Percutaneous sciatic nerve blocks were performed with five lidocaine solutions prepared from either crystalline lidocaine hydrochloride at a concentration of 0.5% or commercial lidocaine at a concentration of 0.5% and 1.0% (Abbott Laboratories;table 1).
Preparation of 0.
5% Solutions from Crystalline Lidocaine Hydrochloride
Five 0.5% lidocaine solutions (all exactly 0.5% with pH = 5.13 or 7.85) were prepared from the crystalline salt: (1) L: 0.5% plain lidocaine hydrochloride (pH = 5.13 ± 0.05)—50 mg lidocaine hydrochloride powder (Sigma Chemical, St. Louis, MO) was dissolved in 10 ml sterile water (Abbott Laboratories); (2) LOH: 0.5% lidocaine hydrochloride alkalinized with NaOH (pH = 7.85)—50 mg lidocaine hydrochloride powder was dissolved in 10 ml sterile water, and the pH was adjusted to 7.85 with 30 μl (1:333) of 2N NaOH (Fisher Scientific, Pittsburgh, PA); (3) LBC: 0.5% lidocaine hydrochloride with 8.4% sodium bicarbonate (10:1; pH = 7.85)—10 ml of 0.55% lidocaine hydrochloride was prepared by dissolving 55 mg lidocaine hydrochloride in 10 ml sterile water; 10 ml of 8.4% sodium bicarbonate was prepared by dissolving 840 mg of sodium bicarbonate powder (Sigma Chemical) in 10 ml sterile water, and 1 ml of this solution was added to the 10-ml lidocaine solution to make a resultant containing 55 mg lidocaine in 11 ml = 0.5%; (4) LE: 0.5% lidocaine with epinephrine (1:100,000) alkalinized with NaOH (pH = 7.85)—100 mg crystalline epinephrine hydrochloride (Sigma Chemical) was dissolved in 10 ml sterile water, and 10 μl of this (1:100) solution was added to 10 ml of 0.5% lidocaine (made as above) to achieve a final epinephrine concentration of 1:100,000; the pH of this solution was adjusted to 7.85 with 40 μl (1:250) of 2N NaOH; and (5) LBCE: 0.5% lidocaine with epinephrine (1:100,000) alkalinized to pH 7.85 with 8.4% sodium bicarbonate (10:1) (pH = 7.85)—this solution was prepared according to the combined regimens 3 and 4, described above. All pHs were measured at room temperature (20–22°C) using a Model 611 pH meter (Orion Research Inc., Boston, MA) with a combination Ag/AgCl-glass electrode (Corning Inc., Acton, MA) in a slowly stirred solution to minimize vortex-induced dissolution of carbon dioxide.
Preparation of Crystalline Control Solutions
Three control solutions were prepared. The first contained only sterile water, the second contained epinephrine dissolved in sterile water to a concentration of 1:100,000 (according to regimen 4), and the third contained 8.4% sodium bicarbonate dissolved in sterile water (according to regimen 3) and diluted to a ratio of 1:10.
Preparation of Commercial 0.
5% Lidocaine Solutions
Five 0.5% lidocaine solutions were prepared from commercially available solutions. The lidocaine concentration in all solutions was exactly 0.5%, and in solutions with NaOH, pH was adjusted to 7.85. In solutions with epinephrine or sodium bicarbonate, there was no intentional adjustment of pH, in order to simulate clinical conditions: (1) CL: 0.5% unalkalinized lidocaine hydrochloride injection (pH = 6.58); (2) CLOH: 0.5% lidocaine hydrochloride alkalinized with NaOH (pH = 7.85)—10 ml of 0.5% lidocaine hydrochloride injection was alkalinized with 10 μl (1:1000) of 2N NaOH; (3) CLBC: 0.5% lidocaine hydrochloride alkalinized with 8.4% sodium bicarbonate (10:1; pH = 7.99)—1% lidocaine hydrochloride injection (Abbott Laboratories) was diluted to 0.55% solution with 0.9% NaCl injection (Abbott Laboratories); 1 ml of 8.4% sodium bicarbonate injection (Abbott Laboratories) was added to 10 ml of the 0.55% lidocaine solution; (4) CLE: 0.5% unalkalinized lidocaine hydrochloride containing epinephrine (1:100,000) injection (Abbott Laboratories; pH = 6.46); and (5) CLBCE: 0.5% lidocaine hydrochloride with 8.4% sodium bicarbonate (10:1) and epinephrine (1:100,000) (pH = 7.85)—1% lidocaine hydrochloride injection was diluted to 0.55% with 0.9% NaCl injection; 1 ml of 8.4% sodium bicarbonate injection was added to 10 ml of the 0.55% lidocaine hydrochloride solution, and 110 μl of epinephrine hydrochloride (1:1000) injection (American Regent Laboratories, Shirley, NY) was added to this solution.
Preparation of Commercial 1.
0% Lidocaine Solutions
Five 1.0% lidocaine solutions were prepared from commercially available solutions. The lidocaine concentration in all solutions was exactly 1.0%, and in solutions with NaOH, pH was adjusted to 7.85. In solutions with epinephrine or sodium bicarbonate there was, again, no intentional adjustment of pH, to simulate clinical conditions: (1) *CL: 1% lidocaine hydrochloride injection (pH = 6.64); (2) *CLOH: 1% lidocaine hydrochloride alkalinized with NaOH (pH = 7.85)—10 ml of 1% lidocaine hydrochloride injection was alkalinized to pH = 7.85 with 15 μl (1:667) of 2N NaOH; (3) *CLBC: 1% lidocaine hydrochloride alkalinized with 8.4% sodium bicarbonate (10:1; pH = 7.75)—a solution of 1.5% lidocaine hydrochloride injection (Abbott Laboratories) was diluted to 1.1% with 0.9% NaCl injection; 1 ml of 8.4% sodium bicarbonate injection was then added to 10 ml of the 1.1% lidocaine solution; (4) *CLE: unalkalinized 1% lidocaine hydrochloride with epinephrine (1:200,000) injection (Abbott Laboratories; pH = 4.46); and (5) *CLBCE: 1% lidocaine hydrochloride with epinephrine (1:200,000) alkalinized with 8.4% sodium bicarbonate (10:1; pH = 7.49)—a solution of 1.5% lidocaine hydrochloride injection was diluted to 1.1% with 0.9% NaCl injection; 1 ml of 8.4% sodium bicarbonate injection was then added to 10 ml of the 1.1% lidocaine solution, and 110 μl of epinephrine hydrochloride injection was then added to this solution.
Preparation of Commercial Control Solutions
Three control solutions were prepared for this component of the study. The first contained only 0.9% NaCl injection, the second contained 1 ml of 8.4% sodium bicarbonate injection combined with 10 ml of 0.9% NaCl injection, and the third contained 100 μl of epinephrine hydrochloride injection (1:1000) combined with 10 ml of 0.9% NaCl injection to make a resultant concentration of 1:100,000.
Injection of Lidocaine Solutions
The injection technique used in this study was the same used by Thalhammer et al. 6and Popitz-Bergez et al. 7to produce a motor and sensory block of the sciatic nerve in a rat. Fifteen groups of rats, each group with n = 9 or 10, received a percutaneous injection with a 27-gauge needle of 100 μl of one of the 15 lidocaine solutions previously described. An additional six groups of rats, each with n = 4, received a percutaneous injection of 100 μl of one of six control solutions.
Evaluation of Sensory Functional Deficit
Analgesia was measured in the ipsilateral limb every 2 min after injection for up to 40 min, and every 10 min thereafter. The neurologic evaluation was a modification of the protocol described by Thalhammer et al. 6Nociception was quantified by evaluating the rat’s withdrawal response to a deep pinch (forceful enough to reach bone) by serrated forceps at the fifth metatarsal. The withdrawal response was graded on an ordinal scale of 0 (no withdrawal response) to 4 (a normal, brisk withdrawal response). A score of 4 meant a normal reaction characterized by a brisk, strong paw withdrawal, vocalization, and an attempt to bite the forceps. A score of 3 was characterized by a slower, weaker withdrawal response, vocalization, and no attempt to bite the forceps. A score of 2 corresponded to an even slower withdrawal response, no vocalization, and no biting of the forceps. A score of 1 was characterized by a very weak attempt to withdraw. And a score of 0 was given when the rat showed none of these responses. Previous reports showed that motor block of the sciatic nerve could not account for withdrawal response deficits, proving that true sensory loss was being tested. 6
Analgesia was reported as the mean withdrawal response to deep pinch ± SD. The duration of block was defined as the time until the response returned to a value of 3 (75% of normal) after injection. The time of onset was the time it took for the response to reach a value of 2 (50% of normal), from a normal response of 4, after injection. The maximum degree of impairment was considered the lowest withdrawal response score achieved after injection of local anesthetic.
The duration of onset, the degree of block, and the duration of block achieved with lidocaine solutions were compared using the Mann–Whitney U rank sum test (SPSS Software, Chicago, IL). Only groups of rats receiving injection of lidocaine solutions at the same concentration (either 0.5% or 1.0%) and prepared from the same materials (crystalline or commercial lidocaine) were compared against each other. Furthermore, only pairwise comparisons were made between either two groups (those receiving injections of lidocaine solutions without epinephrine) or three groups (those receiving injections of lidocaine solutions with epinephrine). Therefore, the criterion for significance was adjusted, using a Bonferroni approximation, to P = 0.025 for pairwise comparison between two groups and P = 0.017 for pairwise comparison between three groups.
Analgesia with 0.
5% Crystalline Lidocaine Solutions
None of the three control solutions (sterile water, 8.4% sodium bicarbonate (1:10), or epinephrine (1:100,000) produced any impairment of nocifensive function, i.e. , a normal withdrawal response of 4 was present for 60 min after injection. Furthermore, there were no indications of motor deficits, such as foot pronation, toe curling, or dragging of the limb.
Considering onset time, alkalinization of 0.5% lidocaine without epinephrine by either NaOH (LOH) or sodium bicarbonate (LBC) produced a faster onset than did unalkalinized lidocaine (L): 3.2 ± 1.3 (P = 0.006) and 2.9 ± 1.0 min (P = 0.0024) versus 6.0 ± 2.1 min (± SD), respectively (fig. 1). Furthermore, onset times with either alkalinizing agent did not differ significantly from each other (P = 0.678). Considering degree of block and duration of block, these parameters did not differ significantly among the three solutions. Mean values (± SD) of the lowest withdrawal response score achieved with the L, LBC, and LOH solutions were 1.2 ± 1.0, 1.0 ± 0.8, and 0.4 ± 0.7, respectively (P ≥ 0.059), and those for duration of block were 15.0 ± 6.2 min, 11.4 ± 3.0 min, and 17.8 ± 7.8 min. Duration of block achieved with the LBC solution was less, but insignificantly so, than that with both L (P = 0.054) and LOH (P = 0.085).
When 0.5% crystalline lidocaine with epinephrine (1:100,000) was alkalinized to pH 7.85 with either sodium bicarbonate or sodium hydroxide, there were no significant differences (P ≥ 0.1) between the two in onset, degree, or duration of block (fig. 2). Mean onset times were 2.8 ± 1.0 min for both, mean withdrawal response scores were 0.0 ± 0.0 for LE and 0.2 ± 0.3 for LBCE, and the mean durations of block were 72.0 ± 16.0 min for LE and 61.0 ± 13.8 min for LBCE.
Analgesia with 0.
5% Commercial Lidocaine Solutions
Sciatic nerve injections with the three control solutions for this component of the study (see Methods) produced no analgesia or motor block indications for 60 min after injection.
Regarding onset time, with 0.5% commercial lidocaine without epinephrine, i.e. , CL, CLBC, and CLOH, it was not possible to compare this parameter among the solutions because several animals never achieved a withdrawal response score of 2, which was the criterion for onset. Assessment of degree of block showed that alkalinization with sodium bicarbonate (CLBC) produced no significant difference in degree of analgesia (mean withdrawal response score was 3.0 ± 0.6) compared with unalkalinized lidocaine (CL, 2.8 ± 1.1;fig. 3). However, alkalinization with sodium hydroxide CLOH resulted in a significantly greater degree of impairment (1.1 ± 1.2) than that with CL (P = 0.017) and CLBC (P = 0.004). With regard to block duration, there were no significant differences between unalkalinized lidocaine (13.2 ± 8.3 min) versus that alkalinized with sodium bicarbonate (4.6 ± 4.6, P = 0.021) or NaOH (12.8 ± 5.5). However, block duration with CLBC was significantly less than that with CLOH (P = 0.006).
Compared with unalkalinized solutions of 0.5% commercial lidocaine with epinephrine (1:100,000; CLE), solutions alkalinized with sodium bicarbonate (CLBCE) produced no significant differences relative to onset (4.0 ± 1.3 min for CLE and 3.8 ± 1.1 min for CLBCE;P = 0.72), degree (a score of 0.0 ± 0.0 for both), or duration of block (61.0 ± 10.4 min for CLE and 57.0 ± 7.8 min for CLBCE;P = 0.3845;fig. 4).
Analgesia with 1.
0% Commercial Lidocaine Solutions
With 1% commercial lidocaine without epinephrine, there were no significant differences relative to onset time among the three solutions (fig. 5): CL was 3.2 ± 1.0 min, CLBC was 2.8 ± 1.4 min, and CLOH was 2.4 ± 0.8 min;P ≥ 0.0752. Relative to degree of block, the addition of sodium bicarbonate (*CLBC) significantly (P ≤ 0.011) decreased the degree of block compared with both unalkalinized lidocaine (*CL) and lidocaine with NaOH (*CLOH). The mean withdrawal response score with *CLBC was 0.8 ± 0.9, and with *CL and *CLOH it was 0.0 ± 0.0. Concerning duration of block, the addition of sodium bicarbonate significantly (P = 0.0002) shortened the duration of block compared with both unalkalinized lidocaine and lidocaine alkalinized with NaOH. Mean duration of block with *CLBC was 14.4 ± 5.1 min; with *CL it was 55.0 ± 13.6 min, and with *CLOH it was 38.0 ± 6.0 min. The duration of block with unalkalinized lidocaine was significantly (P = 0.004) greater than that with NaOH, a finding for which we have no ready explanation.
Adding sodium bicarbonate to 1% lidocaine with epinephrine (1:200,000) hastened the onset compared with unalkalinized (2.4 ± 0.8 for *CLBCE vs. 4.4 ± 1.3 min for *CLE;P = 0.004;fig. 6). However, the addition of bicarbonate did not significantly (P ≥ 0.9281) alter the degree (a mean withdrawal response score of 0.0 ± 0.0 for both) or duration of block (75.6 ± 18.9 min for *CLE and 77.8 ± 11.3 min for *CLBCE).
The results of our investigation show that the effects of sodium bicarbonate on the onset, degree, and duration of peripheral nerve block had two discrete manifestations: (1) they differed with respect to the presence or absence of epinephrine, and (2) they differed with respect to crystalline versus commercial lidocaine.
With 1% commercial lidocaine, bicarbonate decreased degree and duration, lacking any effect on onset when injected without epinephrine. When coinjected with epinephrine, however, the reverse occurred: bicarbonate hastened onset without effecting degree or duration.
Sodium bicarbonate hastened the onset of block induced by 0.5% crystalline lidocaine in solutions without epinephrine. But with 0.5% commercial lidocaine without epinephrine, none of the block parameters were affected by bicarbonate. With the other commercial non–epinephrine-containing solution, i.e. , 1% lidocaine without epinephrine, bicarbonate did not affect onset time but reduced both degree of block (by 25%) and duration of block (by > 50%) compared with lidocaine unalkalinized and alkalinized with NaOH. Sodium bicarbonate alkalinized the pH of this solution to 7.75 ± 0.05. The pH of the unalkalinized solution was 6.64 ± 0.05, whereas that of the solution alkalinized with NaOH was 7.85 ± 0.05. The fact that the pH of the two alkalinized solutions are within each other’s error range indicates that the effect of bicarbonate on 1% lidocaine is probably independent of pH and, rather, a direct effect of bicarbonate itself.
These results show that the onset of rat peripheral nerve block with lidocaine at a low concentration (0.5%) may be accelerated by modest alkalinization, from addition of either sodium hydroxide or sodium bicarbonate, with no perceptible effect on degree or duration. However, at higher concentrations of lidocaine (1.0%) without added epinephrine, the reverse occurs, i.e. , block duration and degree of analgesia are substantially decreased by the addition of sodium bicarbonate without effecting onset, compared with that observed with no alkalinization or alkalinization with NaOH. In contrast, when 1.0% lidocaine is coinjected with epinephrine, bicarbonate hastens onset.
Our finding that adding sodium bicarbonate to 1% commercial lidocaine without epinephrine does not affect onset time has been previously described in clinical studies. It was shown that alkalinization with sodium bicarbonate of 2% commercial lidocaine without epinephrine did not affect the onset of epidural anesthesia 8, nor did it affect the onset of action of 1% lidocaine during subcutaneous injection. 9However, other studies have reported conflicting results. Two investigations have shown that alkalinization with sodium bicarbonate does accelerate the onset time of lidocaine. The addition of sodium bicarbonate to 2% lidocaine produced a faster onset of epidural block in one study 2and of peribulbar anesthesia in another. 5Unfortunately, in none of the clinical studies was the injectate pH reported, before or after adjuvant addition. No clinical studies report the results of addition of NaOH to local anesthetic solutions. We wish to point out that NaOH is not approved for clinical use as an alkalinizing agent for local anesthetics and do not advocate its use for this purpose until rigorous clinical testing of its safety and efficacy is performed.
Our finding that sodium bicarbonate may shorten the block duration of lidocaine when it is not coinjected with epinephrine, compared with unalkalinized and alkalinized with NaOH, conflicts with the results of one study. Parham and Pasieka 9showed that adding sodium bicarbonate to 1% lidocaine without epinephrine did not affect its duration of action after subcutaneous injection.
Precipitation was considered as a possible explanation for the effect of sodium bicarbonate on lidocaine’s duration of action. 10However, no precipitate was observed by visual inspection during any component of our study. Furthermore, lidocaine adjusted to the identical pH with NaOH did not decrease the duration or lessen the degree of analgesia, indicating that precipitation probably did not occur. Because lidocaine solutions at the same pH have the same concentration of the base form of the local anesthetic, one would expect solutions at the same pH to precipitate at the same rate.
At the lower concentration (0.5%) of commercial lidocaine used here, alkalinization with NaOH increased the degree of block almost twofold compared with plain acidic lidocaine hydrochloride. At the higher concentration (1.0%) of commercial lidocaine, this effect of NaOH was not observed because both solutions produced complete nerve block. This effect was only observed with commercial lidocaine solutions, and not with solutions prepared in our laboratory of identical lidocaine concentration but different composition. We cannot explain the differences between commercial lidocaine solutions and crystalline lidocaine hydrochloride solutions in absolute effect or modulation of block by bicarbonate.
Bicarbonate’s reduction of analgesia by lidocaine has not been reported in clinical studies. Curatolo et al. 2found that adding sodium bicarbonate to 2% lidocaine during epidural block at L2–L3 resulted in an apparent potentiation of block, indicated by significantly higher pain thresholds for both repeated electrical stimulation (five pulses at 2 Hz) and pin prick compared with plain lidocaine hydrochloride. The discrepancy between these actions of bicarbonate in the laboratory and clinic may arise from either the different routes of administration (epidural vs. peripheral nerve), the anatomic scale of the blocked nerves (5–10-mm diameter for human spinal roots vs. 1–2 mm for rat sciatic nerve), or the difference in vascular beds at the two loci. Rat and human peripheral nerve fibers have almost identical action potential mechanisms; therefore, the difference is unlikely to reside in the pharmacodynamics of nerve block, i.e. , blockade of action potential caused by inhibition of Na+channels.
With 0.5% lidocaine with epinephrine (1:100,000), there were no differences in degree or duration of block when sodium bicarbonate was added. However, adding sodium bicarbonate to commercial 1% lidocaine with epinephrine (1:200,000) did accelerate the onset. Perhaps this resulted from elevation of the low pH (4.5) of the 1% solution, a situation that often occurs with epinephrine-containing solutions and that would be expected to accelerate block onset.
In regional anesthesia, it is generally believed that alkalinization with sodium bicarbonate reduces pain on injection by increasing pH (acidic solutions per se are algogenic), decreases onset time, and perhaps produces a more complete block by elevating the pH of the lidocaine solutions closer to the pKaof this local anesthetic (7.8), thus favoring the proportion of the deprotonated, membrane-permeant form of the local anesthetic. 11,12Furthermore, ion trapping of charged local anesthetic inside the nerve axons, resulting from axoplasmic acidification, has also been posited, although experimental evidence for this is weak. 13Our investigation has not validated the expectation of enhanced blockade, although the expected physical chemical changes in the drug do occur with alkalinization, and lidocaine block of nerve impulses in vitro is potentiated by bicarbonate. 13–15Sodium bicarbonate alkalinization may reduce onset time, but it also decreases the degree and duration of analgesia. These observations in rats indicate that further clinical investigations are necessary to elucidate the role of sodium bicarbonate alkalinization of plain lidocaine and lidocaine containing epinephrine on the quality of peripheral nerve block.